Dexamethasone decreases IL-29 expression in house dust mite-stimulated human bronchial epithelial cells

Abstract

The aim of this study was to explore the effect of IL-29 on the progression of airway allergic disease by detecting the level of IL-29 in airway allergic cell models stimulated by house dust mite (HDM) in the presence or absence of dexamethasone (DEX). The same batch of human bronchial epithelial cells in exponential growth phase was randomly divided into five groups: blank group (A), 300 ng/mL HDM group (B), 1000 ng/mL HDM group (C), 3000 ng/mL HDM group (D), and 300 ng/mL HDM+100 ng/mL DEX group (E). The IL-29 mRNA expression was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The IL-29 protein expression in cell suspension was detected by ELISA. The results showed that after stimulation with HDM for 24 h, the expression of IL-29 was increased significantly, and after co-stimulation with HDM and DEX for 24 h, the expression of IL-29 in group E was significantly lower than that in the groups stimulated by HDM alone but higher than that in the group A. The differences between the different groups were significant (F=132.957, P<0.01). Additionally, the higher the concentration of HDM was, the more significant the increase in the IL-29 expression was. In conclusion, IL-29 may play a role in the progression of airway allergic disease including asthma.

Keywords

IL-29 / dexamethasone

References

[1] WolkK, WitteK, WitteE, et al. . Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol, 2008, 83(5): 1181-1193 PMID: 18281438

[2] CocciaEM, SeveraM, GiacominiE, et al. . Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol, 2004, 34(3): 796-805 PMID: 14991609

[3] JordanW E e J S n v S, et al. . Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun, 2007, 8(3): 254-261 PMID: 17361203

[4] SirenJ, PirhonenJ, JulkunenI, et al. . IFN-a regulates TLR-dependent gene expreßsion of IFN-a, IFN-ß, IL-28, and IL-29. J Immunol, 2005, 174(4): 1932-1937 PMID: 15699120

[5] BossiosA, GourgiotisD, SkevakiCL, et al. . Rhinovirus infection and house dust mite exposure synergize in inducing bronchial epithelial cell interleukin-8 release. Clin Exp Allergy, 2008, 38(10): 1615-1626 PMID: 18647315

[6] HammadH, ChieppaM, PerrosF, et al. . House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med, 2009, 15(4): 410-416 PMCID: 2789255 PMID: 19330007

[7] BullensDM, DecraeneA, DilissenE, et al. . Type III IFN mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy, 2008, 38(9): 1459-1467 PMID: 18564328

[8] WitteK, GruetzG, VolkHD, LoomanAC, et al. . Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun, 2009, 10(8): 702-714 PMID: 19798076

[9] No authors listed.. Dust mite allergens and asthma—a worldwide problem. J Allergy Clin Immunol, 1989, 83: 416-427

[10] MasciaF, MarianiV, GiannettiA, et al. . House dust mite allergen exerts no direct proinflammatory effects on human keratinocytes. J Allergy Clin Immunol, 2002, 109(3): 532-538 PMID: 11898003

[11] GoughL, SchulzO, SewellHF, et al. . The cysteine protease activity of the major dust mite allergen Der p 1 selectively enhances the immunoglobulin E antibody response. J Exp Med, 1999, 190(12): 1897-1902 PMCID: 2195724 PMID: 10601364

[12] DoyleSE, SchreckhiseH, Khuu-DuongK, et al. . Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology, 2006, 44(4): 896-906 PMID: 17006906

[13] ZhouZ, HammingOJ, AnkN, et al. . Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol, 2007, 81(14): 7749-7758 PMCID: 1933366 PMID: 17507495

[14] KotenkoSV, GallagherG, BaurinVV, et al. . IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol, 2003, 4(1): 69-77 PMID: 12483210

[15] BrandS, BeigelF, OlszakT, et al. . IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol, 2005, 289(5): 960-968

[16] MaherSG, SheikhF, ScarzelloAJ, et al. . IFN-alpha and IFN-lambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther, 2008, 7(7): 47781

[17] PagliaccettiNE, EduardoR, KleinsteinSH, et al. . Interleukin-29 functions cooperatively with interferon to induce antiviralgene expression and inhibit hepatitis C virus replication. J BiolChem, 2008, 283(44): 30079-30089

[18] ZitzmannK, BrandS, BaehsS, et al. . Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun, 2006, 344(4): 1334-1341 PMID: 16650825

[19] LiQ, KawamuraK, MaG, et al. . Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer, 2010, 46(1): 180-190 PMID: 19879751

[20] SatoA, OhtsukiM, HataM, et al. . Antitumor activity of IFN-lambda in murine tumor models. J Immunol, 2006, 176(12): 7686-7694 PMID: 16751416

[21] KirkwoodJM, TarhiniAA, PanelliMC, et al. . Next generation of immunotherapy for melanoma. J Clin Oncol, 2008, 26(20): 3445-3455 PMID: 18612161

[22] RobakT. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev, 2006, 32(5): 365-376 PMID: 16781083

[23] SievertW. Management issues in chronic viral hepatitis: hepatitis C. J Gastroenterol Hepatol, 2002, 17(4): 415-422 PMID: 11982722

[24] Weinstock-GuttmanB, RamanathanM, ZivadinovR. Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther, 2008, 8(9): 1435-1447 PMID: 18694361

[25] ContoliM, MessageSD, Laza-StancaV, et al. . Role of deficient type III interferon-production in asthma exacerbations. Nature Med, 2006, 12(9): 1023-1026 PMID: 16906156

[26] JordanWJ, EskdaleJ, BoniottoM, et al. . Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun, 2007, 8(1): 13-20 PMID: 17082759

[27] PekarekV, SrinivasS, EskdaleJ, et al. . Interferon lambda-1 (IFNlambda1/IL-29) induces ELR-CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. Genes Immun, 2007, 8(2): 177-180 PMID: 17252004

[28] DaiJ, MegjugoracNJ, GallagherGE, et al. . IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood, 2009, 113(23): 5829-5838 PMID: 19346497

[29] JordanWJ, EskdaleJ, SrinivasS, et al. . Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun, 2007, 8(3): 254-261 PMID: 17361203

[30] MennechetF U G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood, 2006, 107(11): 4417-4423 PMID: 16478884